In a real world clinical practice there is a high amount of unpredictable inter-individual TTR variability and in some patients good anticoagulation control is more challenging than in others. These findings may help to identify patients who will require closer monitoring or innovative strategies to optimise the outcomes of oral anticoagulant therapy.
A519for treatment with dabigatran. It is assumed that all diagnosed AF patients eligible for oral anticoagulation currently receive warfarin and that all patients switch to dabigatran in Year 1, regardless of International Normalised Ratio (INR) control amongst warfarin patients. Differences in numbers of clinical events expected to occur based on a patient's antithrombotic treatment were estimated by applying event rates from literature sources. Costs were estimated from a HSE perspective and included costs of clinical events, disability costs and medication costs. Results: A total of 28,332 Irish patients are estimated to have been diagnosed with AF and are eligible for dabigatran. Switching these patients from warfarin to dabigatran may avoid: 657 strokes; 792 major bleeds; 1,437 deaths. By Year 5, cumulative dabigatran drug costs were estimated at € 7,670,870. Cost savings due to clinical events avoided amounted to € 2,894,743 and savings on disability costs at € 5,563,349, giving a total cost saving with dabigatran of € 787,223. ConClusions: Use of dabigatran as compared to warfarin for stroke prevention in AF in the Irish setting may avoid a significant number of clinical events and result in overall cost savings.
A519for treatment with dabigatran. It is assumed that all diagnosed AF patients eligible for oral anticoagulation currently receive warfarin and that all patients switch to dabigatran in Year 1, regardless of International Normalised Ratio (INR) control amongst warfarin patients. Differences in numbers of clinical events expected to occur based on a patient's antithrombotic treatment were estimated by applying event rates from literature sources. Costs were estimated from a HSE perspective and included costs of clinical events, disability costs and medication costs. Results: A total of 28,332 Irish patients are estimated to have been diagnosed with AF and are eligible for dabigatran. Switching these patients from warfarin to dabigatran may avoid: 657 strokes; 792 major bleeds; 1,437 deaths. By Year 5, cumulative dabigatran drug costs were estimated at € 7,670,870. Cost savings due to clinical events avoided amounted to € 2,894,743 and savings on disability costs at € 5,563,349, giving a total cost saving with dabigatran of € 787,223. ConClusions: Use of dabigatran as compared to warfarin for stroke prevention in AF in the Irish setting may avoid a significant number of clinical events and result in overall cost savings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.